- Home
- MPV vs CGEN Comparison
MPV vs CGEN Comparison
Compare MPV & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPV
- CGEN
- Stock Information
- Founded
- MPV 1988
- CGEN 1993
- Country
- MPV United States
- CGEN Israel
- Employees
- MPV N/A
- CGEN N/A
- Industry
- MPV Finance Companies
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPV Finance
- CGEN Health Care
- Exchange
- MPV Nasdaq
- CGEN Nasdaq
- Market Cap
- MPV 183.8M
- CGEN 167.4M
- IPO Year
- MPV N/A
- CGEN 2000
- Fundamental
- Price
- MPV $19.25
- CGEN $1.64
- Analyst Decision
- MPV
- CGEN
- Analyst Count
- MPV 0
- CGEN 0
- Target Price
- MPV N/A
- CGEN N/A
- AVG Volume (30 Days)
- MPV 25.2K
- CGEN 264.8K
- Earning Date
- MPV 01-01-0001
- CGEN 08-05-2025
- Dividend Yield
- MPV 8.71%
- CGEN N/A
- EPS Growth
- MPV N/A
- CGEN N/A
- EPS
- MPV 1.71
- CGEN N/A
- Revenue
- MPV N/A
- CGEN $27,589,000.00
- Revenue This Year
- MPV N/A
- CGEN N/A
- Revenue Next Year
- MPV N/A
- CGEN $173.80
- P/E Ratio
- MPV $9.35
- CGEN N/A
- Revenue Growth
- MPV N/A
- CGEN N/A
- 52 Week Low
- MPV $11.18
- CGEN $1.13
- 52 Week High
- MPV $16.42
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- MPV 74.25
- CGEN 54.29
- Support Level
- MPV $18.47
- CGEN $1.65
- Resistance Level
- MPV $19.32
- CGEN $1.83
- Average True Range (ATR)
- MPV 0.56
- CGEN 0.10
- MACD
- MPV 0.09
- CGEN -0.01
- Stochastic Oscillator
- MPV 72.54
- CGEN 47.50
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.